Reports, Positive Results, Updated Clinical Safety and Efficacy Data by Healthcare Companies - Research Report on Johnson &

   Reports, Positive Results, Updated Clinical Safety and Efficacy Data by
Healthcare Companies - Research Report on Johnson & Johnson, Merck, BioMarin,
                 Array BioPharma, and Brookdale Senior Living

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, December 12, 2013

NEW YORK, December 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), BioMarin Pharmaceutical
Inc. (NASDAQ: BMRN), Array BioPharma, Inc. (NASDAQ: ARRY), and Brookdale
Senior Living Inc. (NYSE: BKD). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Johnson & Johnson Research Report

On December 8, 2013, Janssen Research & Development, LLC (Janssen), a part of
Johnson & Johnson's Janssen Pharmaceutical Companies, reported positive
results from a pivotal Phase 2 global registration study (MCD2001). According
to the Company, siltuximab, which is an investigational compound, along with
best supportive care (BSC), exhibited statistically significant efficacy and a
tolerable safety profile compared with placebo and BSC in treating patients
with the rare disorder Multicentric Castleman's Disease (MCD) who are
HIV-negative and human herpes virus-8 (HHV-8)-negative. Commenting on the
results, the lead study investigator Raymond S. Wong, MBChB, M.D., Prince of
Wales Hospital, The Chinese University of Hong Kong, Hong Kong, stated, "MCD
is a devastating disease that weakens the immune system and may lead to
life-threatening infections." "These results are encouraging and from my
perspective support the potential for siltuximab as a new treatment for these
patients who previously had no approved treatment options." The Full Research
Report on Johnson & Johnson - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Merck & Co. Inc. Research Report

On December 9, 2013, Merck & Co. Inc.'s (Merck) stock went up by 0.34%,
closing the day at $49.56 per share. Over the past three trading days, the
Company's stock went up by 0.51%, compared to the S&P 500 which also went up
0.87% during the same trading period. The Full Research Report on Merck & Co.
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

--

BioMarin Pharmaceutical Inc. Research Report

On December 9, 2013, BioMarin Pharmaceutical Inc.'s (BioMarin) stock decreased
by 0.23%, closing at $70.00 per share. For the previous three trading days,
the Company's stock went down by 0.04%, compared to the Nasdaq composite which
went up by 0.76% during the same trading period. The Full Research Report on
BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9b6c_BMRN

--

Array BioPharma, Inc. Research Report

On December 9, 2013, Array BioPharma, Inc. (Array BioPharma) announced updated
clinical safety and efficacy data on ARRY-614 in patients with myelodysplastic
syndromes (MDS) at the 2013 Annual Meeting of the American Society of
Hematology. Guillermo Garcia-Manero, M.D., Professor, Department of Leukemia,
Division of Cancer Medicine, The University of Texas MD Anderson Cancer
Center, stated, "The emerging results from this study with ARRY-614 are very
promising. ARRY-614 was generally well tolerated in these lower-risk MDS
patients and I am particularly encouraged with the platelet effects observed
in patients with thrombocytopenia, including platelet transfusion
independence. Responses were seen in patients for whom hypomethylating agents
had failed, a group with no available treatment options." Michael Needle,
M.D., Chief Medical Officer, Array BioPharma, also added, "Significant unmet
needs remain in the treatment of MDS. ARRY-614 is thought to operate at the
progenitor cell level, distinct from currently available therapies, offering a
unique mechanism of action for treatment of the cytopenias associated with
MDS." The Full Research Report on Array BioPharma, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/e048_ARRY

--

Brookdale Senior Living Inc. Research Report

On December 9, 2013, Brookdale Senior Living Inc.'s (Brookdale Senior Living)
stock reflected a 0.14% decrease, and closed the day at $28.14 per share. The
Company's stock went down by 1.12% during the past three trading days,
compared to the Dow Jones Industrial Average which went up by 0.85% over the
same trading period. The Full Research Report on Brookdale Senior Living Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fefe_BKD

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.